You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
我武生物(300357.SZ)申請專項課題“黃花蒿粉滴劑”III期臨牀及增加兒科適應症的臨牀研究獲立項支持
格隆匯 12-26 21:44

格隆匯12月26日丨我武生物(300357.SZ)公佈,近日,公司收到國家衞生健康委醫藥衞生科技發展研究中心下發的《關於重大新藥創制科技重大專項2019年度實施計劃立項課題的通知》(衞科專項函[2019]764號)。公司申請的專項課題《“黃花蒿粉滴劑”III期臨牀及增加兒科適應症的臨牀研究》獲得立項支持。

課題名稱:“黃花蒿粉滴劑”III期臨牀及增加兒科適應症的臨牀研究;課題編號:2019ZX09301003;課題責任單位:浙江我武生物科技股份有限公司;課題負責人:胡賡熙;課題執行年限:2019年1月—2020年12月;課題資助方式:事前立項事前補助;課題經費:總經費2503.7萬元,其中中央財政經費503.7萬元。

課題主要研製一種用於由蒿屬花粉引起的過敏性疾病的新型脱敏疫苗——“黃花蒿粉滴劑”。目前該品種已提出藥品註冊申請(申報生產,受理號:CXSS1900020)。在該課題實施期將力爭獲得該品《註冊批件》與《新藥證書》。此外,基於兒童花粉過敏性疾病患者眾多,在該課題實施期內,將開展兒童過敏性鼻炎療效與安全性臨牀研究。

《“黃花蒿粉滴劑”III期臨牀及增加兒科適應症的臨牀研究》課題被成功列入“重大新藥創制”科技重大專項立項課題,是對公司該項目的高度認可,專項課題的實施有助於強化企業技術創新的主體地位。未來公司會繼續加強研發和科技創新的轉化與應用,提升自主創新能力。

目前公司已收到中央財政經費資金503.7萬元,該筆經費將計入遞延收益,最終會計處理須以會計師事務所年度審計確認後的結果為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account